DK0831787T3 - Sammensætning til vedvarende frigivelse af humant væksthormon - Google Patents

Sammensætning til vedvarende frigivelse af humant væksthormon

Info

Publication number
DK0831787T3
DK0831787T3 DK96919016T DK96919016T DK0831787T3 DK 0831787 T3 DK0831787 T3 DK 0831787T3 DK 96919016 T DK96919016 T DK 96919016T DK 96919016 T DK96919016 T DK 96919016T DK 0831787 T3 DK0831787 T3 DK 0831787T3
Authority
DK
Denmark
Prior art keywords
composition
sustained release
hgh
biologically active
polymer
Prior art date
Application number
DK96919016T
Other languages
English (en)
Inventor
Howard Bernstein
Olufunmi Lily Johnson
Medha M Ganmukhi
Henry Auer
M Amin Khan
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/473,544 external-priority patent/US5654010A/en
Application filed by Alkermes Inc filed Critical Alkermes Inc
Application granted granted Critical
Publication of DK0831787T3 publication Critical patent/DK0831787T3/da

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK96919016T 1995-06-07 1996-06-03 Sammensætning til vedvarende frigivelse af humant væksthormon DK0831787T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/473,544 US5654010A (en) 1992-12-02 1995-06-07 Composition for sustained release of human growth hormone
US08/477,725 US5667808A (en) 1992-12-02 1995-06-07 Composition for sustained release of human growth hormone
PCT/US1996/008086 WO1996040072A2 (en) 1995-06-07 1996-06-03 Composition for sustained release of human growth hormone

Publications (1)

Publication Number Publication Date
DK0831787T3 true DK0831787T3 (da) 2001-12-17

Family

ID=27044171

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96919016T DK0831787T3 (da) 1995-06-07 1996-06-03 Sammensætning til vedvarende frigivelse af humant væksthormon

Country Status (21)

Country Link
EP (1) EP0831787B1 (da)
JP (1) JPH11506740A (da)
CN (1) CN1102854C (da)
AT (1) ATE204468T1 (da)
AU (1) AU708756B2 (da)
BR (1) BR9608542A (da)
CA (1) CA2223436A1 (da)
CZ (1) CZ288147B6 (da)
DE (1) DE69614685T2 (da)
DK (1) DK0831787T3 (da)
ES (1) ES2161366T3 (da)
HU (1) HUP9900870A3 (da)
IL (1) IL122385A (da)
MX (1) MX9709698A (da)
NO (1) NO316104B1 (da)
NZ (1) NZ310644A (da)
PL (1) PL184531B1 (da)
PT (1) PT831787E (da)
RU (1) RU2161502C2 (da)
SK (1) SK281571B6 (da)
WO (1) WO1996040072A2 (da)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6242096A (en) * 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
WO1998027980A2 (en) * 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
AR012448A1 (es) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
NZ508878A (en) 1998-05-15 2003-08-29 Genentech Inc IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
EP1978029A3 (en) 1999-06-15 2008-10-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
EP1672070A3 (en) 1999-12-01 2006-10-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DK1897944T3 (da) 1999-12-23 2011-10-24 Genentech Inc IL-17 homologe polypeptider og terapeutisk anvendelse deraf
CA2397207C (en) 2000-01-13 2013-12-03 Genentech, Inc. Novel stra6 polypeptides
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
CA2402191C (en) 2000-03-24 2012-03-13 Genentech, Inc. Use of insulin for the treatment of cartilagenous disorders
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2014298A3 (en) 2000-08-24 2009-10-07 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
CA2433037C (en) 2000-12-28 2010-12-21 Takeda Chemical Industries, Ltd. Sustained-release preparation
WO2002092619A2 (en) 2001-05-14 2002-11-21 The Gouvernment Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
AU2002320122B2 (en) 2001-06-21 2007-07-26 Genentech, Inc. Sustained release formulation
SI1485477T1 (sl) 2002-02-25 2009-10-31 Genentech Inc Novi citokinski receptor GLM-R tipa 1
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
MXPA05013181A (es) 2003-06-06 2006-06-23 Genentech Inc Metodos y composiciones para modular hgf/met.
PL2784084T5 (pl) 2003-07-08 2024-12-02 Novartis Pharma Ag Przeciwciała antagonistyczne heterologicznych polipeptydów il-17a/f
US20050233960A1 (en) 2003-12-11 2005-10-20 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
PL1745069T3 (pl) 2004-03-30 2009-10-30 Nsgene As Zastosowanie terapeutyczne czynnika wzrostu NSG33
SG156680A1 (en) 2004-10-27 2009-11-26 Univ Florida Adrenocorticotropic hormone analogs and related methods
EP2295036A2 (en) 2004-12-10 2011-03-16 Talima Therapeutics, Inc. Liquid compositions and methods for treating conditions of the nail unit
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
CA2610709A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
US8389469B2 (en) 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
DK1899378T3 (da) 2005-06-21 2010-02-01 Xoma Technology Ltd IL-1 beta-bindende antistoffer og fragmenter deraf
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
US7931902B2 (en) 2005-08-15 2011-04-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP2360248A1 (en) 2005-08-24 2011-08-24 The Rockefeller University Ply-GBS mutant lysins
WO2007081608A2 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
NZ568809A (en) 2005-12-22 2011-08-26 Genentech Inc Recovering and purification of VEGF proteins from prokaryotic cells using polyanionic agents
US20080311107A1 (en) 2006-02-17 2008-12-18 Genetech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
EP2389947A1 (en) 2006-03-23 2011-11-30 Novartis AG Anti-tumor cell antigen antibody therapeutics
ES2487637T3 (es) 2006-04-10 2014-08-22 Genentech, Inc. Moduladores de PDZ Disheveled
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
AU2007289344B2 (en) * 2006-08-31 2011-04-14 Novartis Ag Pharmaceutical compositions comprising hGH for oral delivery
CA2673592C (en) 2006-12-20 2014-03-25 Xoma Technology Ltd. Methods for the treatment of il-1.beta. related diseases
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
US8933197B2 (en) * 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
US8637029B2 (en) 2007-12-20 2014-01-28 Xoma Technology Ltd. Methods for the treatment of gout
GB0812742D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
MX368790B (es) 2009-10-15 2019-10-16 Genentech Inc Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada.
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
WO2011088318A1 (en) 2010-01-15 2011-07-21 University Of Medicine And Dentistry Of New Jersey Use of vanadium compounds to accelerate bone healing
CN104998269B (zh) 2010-03-22 2019-06-11 弗·哈夫曼-拉罗切有限公司 对于稳定含有蛋白质的制剂有用的组合物和方法
KR20130060227A (ko) 2010-05-03 2013-06-07 제넨테크, 인크. 단백질-함유 제제의 점도 감소에 유용한 조성물 및 방법
SG186783A1 (en) 2010-06-24 2013-02-28 Genentech Inc Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
JP6149226B2 (ja) 2010-10-01 2017-06-21 ホーバ セラピューティクス アンパルトセルスカブ アロディニア、痛覚過敏、自発痛及び幻肢痛の処置
KR101687060B1 (ko) 2010-10-08 2016-12-15 상하이 켁신 바이오테크 씨오., 엘티디. 모에신 조절제 및 그의 용도
EP2624852B1 (en) 2010-10-08 2016-12-14 Shanghai Kexin Biotech Co., Ltd Diagnostic and therapeutic uses of moesin fragments
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
WO2012149334A2 (en) 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
CN102875683B (zh) * 2011-07-11 2014-06-11 旭华（上海）生物研发中心有限公司 长效重组人生长激素的Fc融合蛋白
RU2665810C2 (ru) 2011-10-31 2018-09-04 Дженентек, Инк. Содержащие антитела составы
US20150017157A1 (en) 2011-12-19 2015-01-15 Xoma (Us) Llc Methods for treating acne
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
EP3663314A1 (en) 2012-01-09 2020-06-10 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
CA2904703A1 (en) 2013-03-14 2014-10-02 Hallux, Inc. Method of treating infections, diseases or disorders of nail unit
EP2968548B1 (en) 2013-03-15 2020-09-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
AU2014290361B2 (en) 2013-07-18 2019-04-18 Taurus Biosciences, Llc Humanized antibodies with ultralong complementarity determining regions
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
CN105792851B (zh) 2013-09-13 2023-10-10 斯克利普斯研究所 修饰的治疗剂及其组合物
KR102339240B1 (ko) 2013-10-15 2021-12-15 더 스크립스 리서치 인스티튜트 펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
EP3057991B8 (en) 2013-10-15 2019-09-04 The Scripps Research Institute Chimeric antigen receptor t cell switches and uses thereof
CN104623639A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 白介素22二聚体在制备治疗胰腺炎药物中的应用
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
AU2014364589B2 (en) 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
NL2014230B1 (en) 2015-02-04 2016-10-12 Stichting Vu-Vumc Wound healing formulation.
MA41629A (fr) 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
WO2017181143A1 (en) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Use of il-22 in treating necrotizing enterocolitis
CN110267982B (zh) 2016-10-19 2024-02-23 斯克利普斯研究所 具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
CA3103265A1 (en) 2018-06-12 2019-12-19 Angiex, Inc. Antibody-oligonucleotide conjugates
BR112021019612A2 (pt) 2019-04-01 2021-11-30 Genentech Inc Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa
KR20220061977A (ko) 2019-08-12 2022-05-13 퓨리노미아 바이오테크, 아이엔씨. Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물
WO2021081440A2 (en) 2019-10-24 2021-04-29 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
AU2020397917A1 (en) 2019-12-04 2022-06-23 The Scripps Research Institute GLP2 receptor agonists and methods of use
EP4106794A4 (en) 2020-02-19 2024-03-20 Evive Biotechnology (Shanghai) Ltd METHOD FOR TREATING TRANSPLANT AND HOST DISEASE
WO2022232321A1 (en) 2021-04-28 2022-11-03 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
KR20240006581A (ko) 2021-05-06 2024-01-15 호바 세라퓨틱스 에이피에스 화학요법-유도된 신경병성 통증의 예방 및 치료
MX2023014771A (es) 2021-06-09 2024-03-19 Scripps Research Inst Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.
CA3239550A1 (en) 2021-12-10 2023-06-15 Kenneth Petersen Treatment of nociceptive pain
JP2025515486A (ja) 2022-04-29 2025-05-15 ピュリノミア バイオテック， インコーポレイテッド 好酸球駆動性疾患及び障害を治療するための方法及び組成物
WO2025076280A1 (en) 2023-10-05 2025-04-10 Ashibio, Inc. Methods and compositions for treating mmp-9 mediated disorders
WO2026076260A1 (en) 2024-10-03 2026-04-09 Ashibio, Inc. Methods and compositions for mmp-9 inhibition for use with non-genetic heterotopic ossification disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
HUT35524A (en) * 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
WO1994012158A1 (en) * 1992-12-02 1994-06-09 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
DE69426292T2 (de) * 1993-02-23 2001-05-17 Genentech, Inc. Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff
DK0779806T3 (da) * 1994-09-09 2000-11-27 Takeda Chemical Industries Ltd Præparat til forsinket frigivelse indeholdende et metalsalt af et peptid

Also Published As

Publication number Publication date
AU6146996A (en) 1996-12-30
CN1102854C (zh) 2003-03-12
IL122385A0 (en) 1998-06-15
NO975708L (no) 1998-02-05
IL122385A (en) 2001-01-11
NZ310644A (en) 1999-08-30
MX9709698A (es) 1998-07-31
CZ390797A3 (cs) 1998-07-15
ES2161366T3 (es) 2001-12-01
HUP9900870A2 (hu) 1999-09-28
BR9608542A (pt) 1999-11-30
PL323832A1 (en) 1998-04-27
HUP9900870A3 (en) 2001-04-28
CZ288147B6 (en) 2001-05-16
PT831787E (pt) 2002-02-28
CN1187120A (zh) 1998-07-08
EP0831787B1 (en) 2001-08-22
DE69614685T2 (de) 2002-06-27
RU2161502C2 (ru) 2001-01-10
WO1996040072A2 (en) 1996-12-19
CA2223436A1 (en) 1996-12-19
JPH11506740A (ja) 1999-06-15
WO1996040072A3 (en) 1997-01-23
ATE204468T1 (de) 2001-09-15
SK281571B6 (sk) 2001-05-10
SK167197A3 (en) 1998-06-03
DE69614685D1 (de) 2001-09-27
PL184531B1 (pl) 2002-11-29
NO316104B1 (no) 2003-12-15
AU708756B2 (en) 1999-08-12
EP0831787A2 (en) 1998-04-01
NO975708D0 (no) 1997-12-05
HK1009089A1 (en) 1999-09-10

Similar Documents

Publication Publication Date Title
DK0831787T3 (da) Sammensætning til vedvarende frigivelse af humant væksthormon
MX9709699A (es) Composicion para la liberacion sostenida de eritropoyetina no agregada.
DE3685958T2 (de) Durch ultraschall gesteuerte polymere vorrichtungen zur wirkstoffabgabe.
CA2474698A1 (en) Polymer-based compositions for sustained release
ATE315409T1 (de) Verbesserte formulierung zur gesteuerten arzneistofffreisetzung durch kombination hydrophiler und hydrophober stoffe
WO2001058474A3 (en) Microencapsulation and sustained release of biologically active agent
ATE433318T1 (de) Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
UA35569C2 (uk) Композиція для пролонгованого і контрольованого вивільнення пептидної лікарської речовини і спосіб її одержання, спосіб приготування суспензії, що призначена для парентерального введення
ATE228832T1 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
UA29563C2 (uk) Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
JPH07187994A (ja) 薬物放出制御製剤
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
DE69840495D1 (de) Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
DK1011637T3 (da) Modulation af fyldning af lægemiddel i multivesikulære liposomer
CA2224074A1 (en) System and method for producing drug-loaded microparticles
EP1570823A3 (en) Substained analgesia achieved with buprenorphine
ATE260651T1 (de) Pharmazeutische ciclosporin-formulierung mit verbesserten biopharmazeutischen eigenschaften, erhöhter physikalischer qualität & stabilität sowie verfahren zur herstellung
AU7004194A (en) Drug system
DE69833375D1 (de) Implantate zur gesteuerten freisetzung von pharmazeutischen wirkstoffen und verfahren zur herstellung
EP0709088B1 (de) Transdermales therapeutisches System zur Applikation von Naloxon
DE59807891D1 (de) Transdermales therapeutisches system (tts) enthaltend ammoniogruppenhaltige (meth)acrylatpolymere zur verabreichung von levonorgestrel
AU5673399A (en) Compositions and methods for treating intracellular infections
WO2020166820A1 (ko) 피나스테라이드를 포함하는 마이크로 입자를 함유한 피하 주사용 조성물